Amphastar Pharmaceuticals, Inc. Stock

Equities

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
38.65 USD -3.50% Intraday chart for Amphastar Pharmaceuticals, Inc. -3.74% -37.51%
Sales 2024 * 777M Sales 2025 * 862M Capitalization 1.89B
Net income 2024 * 192M Net income 2025 * 225M EV / Sales 2024 * 2.77 x
Net Debt 2024 * 260M Net Debt 2025 * 41.48M EV / Sales 2025 * 2.24 x
P/E ratio 2024 *
10.7 x
P/E ratio 2025 *
9.1 x
Employees 1,761
Yield 2024 *
-
Yield 2025 *
-
Free-Float 63.31%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing MT
JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60 MT
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Amphastar Pharmaceuticals Q4 Adjusted Earnings, Revenue Rise MT
Transcript : Amphastar Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023 CI
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Posts Q4 EPS $0.88, vs. Street Est of $0.91 MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q4 Revenue $178.1M, vs. Street Est of $173.3M MT
High-dose opioid reversal spray no better than lower dose in field, US study finds RE
Amphastar Pharmaceuticals Insider Sold Shares Worth $7,171,768, According to a Recent SEC Filing MT
Amphastar Pharmaceuticals Insider Sold Shares Worth $12,798,708, According to a Recent SEC Filing MT
Transcript : Amphastar Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals MT
More news
1 day-3.50%
1 week-3.74%
Current month-11.98%
1 month-9.80%
3 months-31.51%
6 months-18.11%
Current year-37.51%
More quotes
1 week
38.43
Extreme 38.43
41.65
1 month
38.43
Extreme 38.43
44.89
Current year
38.43
Extreme 38.43
65.92
1 year
35.62
Extreme 35.62
67.66
3 years
17.01
Extreme 17.01
67.66
5 years
12.33
Extreme 12.325
67.66
10 years
8.32
Extreme 8.32
67.66
More quotes
Managers TitleAgeSince
Founder 74 96-02-28
Chief Executive Officer 77 96-02-28
Director of Finance/CFO 56 14-03-31
Members of the board TitleAgeSince
Director/Board Member 67 03-01-31
Director of Finance/CFO 56 14-03-31
Director/Board Member 64 01-05-31
More insiders
Date Price Change Volume
24-04-18 38.65 -3.50% 329,460
24-04-17 40.05 -2.08% 494,599
24-04-16 40.9 +0.29% 305,212
24-04-15 40.78 +2.93% 403,717
24-04-12 39.62 -1.32% 392,144

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.65 USD
Average target price
62.6 USD
Spread / Average Target
+61.97%
Consensus